Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elevenostat
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- None
01
Overview
Elevenostat (JB3-22) is a selective, small molecule inhibitor of histone deacetylase 11 (HDAC11), with an IC50 of 0.235 μM. It is a hydroxamic acid derivative that has demonstrated the ability to reverse the inhibitory effects of HDAC11 on Foxp3 acetylation, thereby promoting regulatory T cell (Treg) suppressive activity. Preclinical research suggests anti-tumor effects, including inducing apoptosis in multiple myeloma cells and improving survival in murine myeloma models. Elevenostat is used exclusively in research settings and is not approved for human or clinical use[1][2][3][4][5][9].
- Other names
- JB3-22JB-3-22JB 3-22
02
Targets
HDAC11 (Histone Deacetylase 11)
Beyond the preview
Go deeper on elevenostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elevenostat.